OR WAIT null SECS
December 19, 2016
The US molecular diagnostics market will reach $6.55 billion by 2021, according to analysis by Frost & Sullivan’s Life Sciences Growth Partnership Service. Polymerase chain reaction (PCR), next-generation sequencing (NGS), microarray, and fluorescent in situ-hybridization (FISH) are the dominant technologies in the space, it is reported. “With the right strategies, molecular diagnostics companies will see high adoption of their technologies in hospitals and clinical settings, especially in point-of-care testing for rapid diagnosis of multiple infectious diseases,” said Transformational Health Research Analyst Aish Vivekanadan. “Increasing clinical validations will also go a long way with the FDA and user bases, eventually spurring collaborations for pharmacogenomics and enabling personalized medicine.” For more information, click here.